Adhesion of B cell precursors to accessory cells in the bone marrow microenvironment may be required for normal early B cell development. Human bone marrow B cell precursors adhere more avidly than mature B cells to bone marrow-derived fibroblasts. To determine the mechanism of this adhesion, expression of adhesion proteins on human B precursor cells and cell lines was measured by flow cytometry. The very late antigen (VLA) integrins VLA4 and VLA-5 were the only adhesion proteins expressed at higher levels in B cell precursors than mature B cells.
Introduction
The earliest identifiable B lineage precursors are found in the bone marrow. In vitro culture systems that support the proliferation of mouse B cell precursors are dependent on interaction between the B cell precursors and a layer of adherent bone marrow-derived accessory cells (1) . Developing B cells lie within membrane infoldings (2) of specific subpopulations of adherent cells (3) and are dependent on contact with these cells for their continued growth (4) . This intimate contact between developing B cells and stromal cells is also observed in vivo (5) . Adhesion to bone marrow-derived adherent cells is character-etic growth factors such as stem cell factor (kit ligand [9] ), granulocyte/macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interleukins 6 and 7. Although these factors are capable of affecting hematopoietic precursor cells in the absence of stromal cells, in vivo hematopoiesis and lymphopoiesis are likely to require close contact between progenitors and stroma, since growth factors may rapidly diffuse into the intercellular space or be expressed in a transmembrane form by stroma, as is the case with stem cell factor (9) . In vitro culture ofnormal human B cell precursors remains a challenge (10) , but it is likely that stromal cell interactions are important in human B lymphopoiesis as well (1 1) .
Stages in human B cell precursor differentiation can be identified by expression of surface markers such as CD10, CD20, and CD34 (12) . We have previously observed that adhesion of normal human B cell precursors to bone marrowderived fibroblasts (BM-FB)' decreases continuously during B cell precursor maturation (13) . B cell precursors adhere more avidly to BM-FB than to dermal fibroblasts or other adherent layers (13) .
The proteins responsible for adhesion of human or murine B cell progenitors to BM-FB are at present unknown. Monoclonal antibodies to the adhesion protein CD44 (gp9OHCIS) block lymphopoiesis in long-term murine bone marrow cultures (14) , but do not actually inhibit the adhesion of normal B cell precursors to the adherent cells. Murine B cell precursors bind to fibronectin (15) , suggesting a possible role for an integrin fibronectin receptor. However, normal human B cell precursors adhere only weakly to fibronectin (13) .
It would be expected that the molecule responsible for adhesion of B cell precursors to BM-FB should be expressed by immature cells and decrease during maturation. However, expression ofthose adhesion proteins which have been measured on human B cell precursors (LFA-1, CD44, and LECAM1) increases during B cell development (16) . Therefore, we investigated the expression and functional activity of additional adhesion proteins on human B cell precursors.
Adhesion receptors are found in at least four protein families (17): integrins; selectins (18) , e.g., LECAM1 (Leu 8), LE-CAM2 (ELAM-1), LECAM3 (GMP-140); cartilage-link proteins, e.g., CD44; and members ofthe immunoglobulin superfamily, e.g., CD56 (NCAM), CD54 (ICAM-1), vascular cell adhesion molecule-I (VCAM-1). Integrins consist of noncovalently linked a-and /3 chains and are classified according to their /3 chain into the very late antigen (VLA) integrins (/3k), leukocyte integrins (/2), cytoadhesin integrins (/3), and additional molecules expressing /4 or /3p chains. The /l3 integrin (VLA) subfamily is widely expressed in both hematopoietic and nonhematopoietic cells, and contains seven members, distinguished by association ofdifferent a chains with the integrin fl, chain (19) . The hematopoietic expression ofsome VLA integrins is limited to T cells (VLA-1, -2, -6) or platelets (VLA-2, -6), but VLA-4 and VLA-5 are widely expressed in lymphoid and hematopoietic cells (17) . We demonstrate here that normal human B cell precursors express VLA-4 and VLA-5 and bind to BM-FB by means of a VLA-4/VCAM-I interaction.
Methods
Cells. Blood and bone marrow samples (posterior iliac crest) were obtained from 20 normal adult volunteer donors with informed consent and light density cells were separated by Ficoll/Hypaque density gradient centrifugation. The 7-29-6 and WIL-2 (20) cell lines were obtained from Dr. Andrew Saxon, University ofCalifornia, Los Angeles. NALM-6 cells were obtained from Dr. Tucker LeBien, University of Minnesota, and Reh cells from Dr. Jun Minowada, Hayashibara Biochemical Laboratories, Okayama, Japan.
Adherent cells and matrix. Marrow fibroblasts were prepared as previously described (13) . Briefly, light density marrow cells were cultured in McCoy's 5A culture medium (Gibco Laboratories, Grand Island, NY) with 10% fetal calf serum, penicillin, and streptomycin ("culture medium"), and the adherent cells were passaged weekly before seeding into Falcon 24-well plates (Becton-Dickinson, Lincoln Park, NJ) at least 1 wk before each binding experiment. Skin fibroblasts were prepared from human foreskin fibroblasts passaged in a similar fashion. Fibronectin and collagen-coated wells were prepared as described (13) (12) . Cells were stained as described (12) , incubating first with CD1O PE and unconjugated antibody, followed by FITC-conjugated goat anti-mouse Ig specific for the isotype ofthe unconjugated antibody used. Blood mononuclear cells were stained with CD20 biotin plus unconjugated adhesion protein antibody followed by avidin PE plus FITC-conjugated goat anti-mouse Ig specific for the isotype of the unconjugated antibody used. Two antibodies were available as direct fluorochrome conjugates: CDl lb FITC and Leu 8 PE. These antibodies were used in a single incubation step with CDO0 PE or CD20 PE (for CDl lb FITC), or with CDIO FITC or CD20 FITC (for Leu 8 PE) to stain bone marrow or blood, respectively. Cell lines were stained with antibody to the adhesion protein, followed by FITC-conjugated goat antimouse Ig.
After staining, fresh cells were held overnight at 40C in medium before flow cytometry analysis. In the case of Leu 8 (but none of the other antibodies used), fluorescence decreased after overnight storage, possibly due to shedding of antigen (23). Therefore, for Leu 8 analysis, cells were stained and analyzed on the same day.
Stained cells were analyzed on a flow cytometer (EPICS C, Coulter Corp.) using standard light scatter gates for mononuclear cells (12) to obtain a two parameter histogram of log green fluorescence (FITC) vs. log red fluorescence (PE). For determination of adhesion protein expression ofbone marrow cells, the mean log green fluorescence channel of the CDlO'I cells (red fluorescence channel > 42) was determined separately from the CDOIO" cells (red fluorescence channels 26-41). For peripheral blood cells, the mean log green fluorescence channel of all CD20-positive cells was determined. The mean log green fluorescence channel ofthe cell lines was determined directly from a single parameter histogram.
The mean log fluorescence channel was converted to linear equivalents as previously described (12) Binding assay. Binding experiments were performed as previously described (13) with minor modifications. Briefly, 106 light density marrow or blood cells in 100 ul of culture medium were added to previously prepared adherent cells or matrix in 24-well plates containing 200 Ml of culture medium. After a 2-h incubation at 370C, nonadherent cells were removed by four washes with culture medium. After these washes, adherent marrow cells were removed by two forceful washes with medium, which did not disturb the fibroblast layer. Viable cell counts ofthe starting cell suspension and the adherent marrow cells were performed on a hemocytometer using propidium iodide. Cells were stained in one step with CD20 FITC and CD IO PE and analyzed on an EPICS C flow cytometer to enumerate CDl0+/CD20-, CDI0+/ CD20+, and CD10-/CD20+ cells as previously described (13) . Each experiment was performed in triplicate wells, which were incubated, counted, stained, and analyzed separately. The percent adherent cells in each B lineage subpopulation was calculated as described (13) . Briefly, the absolute number ofeach B cell subpopulation added to the well at the beginning ofthe adhesion assay was determined by multiplying the total number of bone marrow cells added to the well by the percent positive cells in that B cell subpopulation as determined by flow cytometry. In a similar fashion, the absolute number of each B cell subpopulation recovered in the adherent fraction was determined by multiplying the total number of adherent bone marrow cells by the percent positive cells in that B cell subpopulation as determined by flow cytometry. The percent adherent cells in a B cell subpopulation is based on the ratio of the absolute number of cells recovered in the adherent fraction divided by the absolute number of cells in that subpopulation added to the well.
In experiments with PMA, PMA in ethanol was added in a final concentration of 1.6 nM (final ethanol concentration 0.1 %) to the incubation mixture after 1.5 h of incubation. This concentration and time course was shown to be most effective in enhancing adhesion of bone marrow B lineage cells by dose-response and time course experiments. The controls for these experiments (treated with 0.1% ethanol alone) showed similar results to controls without ethanol.
Blocking studies. 106 light density marrow or blood cells in 100 ,d of culture medium were incubated with 0.9 Mg of blocking antibody (1:2 dilution for BIIG2 culture supernatant) or isotype matched irrelevant antibody and incubated for 30 min at 230C before adding to previously prepared adherent cells or matrix in 24-well plates, making up a final volume of 300 Ml per well (final antibody concentration of 3 Mg/ml). The peptides GRGDSP and GRGESP(identified by the standard single-letter designation for amino acids) were used at 1 mM, and FN-40 at 100 gg/ml final concentration. The cells were then incubated and washed as described above. To block adhesion using antibodies to components of the adherent layer (i.e., fibronectin, collagen, CD54, VCAM-1), the appropriate antibody (3 Mg/ml for CD54; undiluted culture supernatant for anti-VCAM-I [dialyzed against culture medium to remove azide]; 1:40 dilution for polyclonal antibodies) was incubated with the adherent layer for 30 min at 230C before addition ofthe cells.
In experiments designed to block PMA-induced adhesion, blocking reagents were added as described above, and PMA was added to the wells containing cells and adherent layer after 1.5 h of incubation (in the continuing presence of antibody).
Fluorescence staining ofBM-FB. For phenotypic analysis of BM-FB, trypsinized BM-FB were seeded into eight-well slide chambers (Nunc, Inc. Naperville, IL) instead of 24-well plates, and allowed to reach confluency. Adherent cells were incubated in situ with anti-VCAM-1 (1:2 dilution of culture supernatant), anti-CD49d, anti-CD54, anti-fibronectin, or control antibody for 30 min at 230C, then washed thrice with culture medium, incubated with FITC-conjugated goat anti-mouse Ig, then washed again. After the last wash, the culture chambers were removed from the slide, the cells were fixed in 2% paraformaldehyde, and a coverslip was placed over the stained cells for fluorescence microscopy analysis.
Results
Adhesion ofBprecursor cell lines to BM-FB and matrix components. The adhesion of four B lineage cell lines was compared to that of the corresponding normal B lineage cells in the bone marrow. The leukemic cell lines NALM-6 and Reh are CD 19+/ CDI0+/TdT+/surface Ig-, a B cell precursor phenotype. The transformed B cell lines 7-29-6 and WIL-2 are CD I 9+/CD 10-/ TdT-/surface Ig', a mature B cell phenotype. As is shown in Fig. 1 , the two precursor cell lines showed significantly higher adhesion to BM-FB than to dermal FB, whereas two mature B cell lines were much less adherent to the BM-FB and did not show significantly higher binding to BM-FB than to dermal FE. NALM-6 bound less well to fibronectin (adhesion 27±5%; n = 7), collagen (6±3.0%; n = 5), or laminin (0.1±0.1%; n = 3) than to BM-FB (41±8%; n = 7).
Expression ofadhesion proteins by B lineage cells. In order to determine which molecules might be responsible for the adhesion of B lineage precursors to BM-FB, the expression of adhesion-related surface molecules on normal B lineage cells and cell lines was determined using two-color immunofluorescence as shown in Fig. 2 (Fig. 4) , but the pattern was qualitatively similar to that found on normal marrow B lineage cells. Immature B cell lines (NALM-6 and Reh) expressed only VLA-4 and VLA-5, whereas mature B cell lines (WIL-2, 7-29-6, Daudi) lacked VLA-5, and expressed lower levels of VLA4, but were positive for CDl la, CD18, CD44, CD6 1, and CD54.
Inhibition ofadhesion by blocking antibodies andpeptides. In order to determine which ofthe expressed adhesion proteins was actually responsible for adhesion to BM-FB and fibronectin in our in vitro model, inhibition studies with blocking antibodies and peptides were performed.
Each ofthe adhesion receptor antibodies or reagents used in the inhibition experiments blocks adhesion at the concentration used. Aggregation and adhesion of phorbol treated 7-29-6 cells to BM-FB, which is largely dependent on LFA-1/ICAM-1 interaction, was blocked by CD18 (83%) and CD54 (59%) antibodies. Binding of NALM-6 cells to fibronectin was inhibited by 84% (± 13%; n = .3) by anti-fibronectin antibody. Binding of NALM-6 cells to collagen I was 90% (n = 2) inhibited by the mixture of anti-collagen I and IV antibodies used in these experiments. CD29 and CD49d antibodies inhibited adhesion of normal B cell precursors and cell lines as described below.
GRGDS was used at an inhibitory concentration (1 mM). The CD49e antibody used (BIIG2) was used at a concentration demonstrated to show blocking ofVLA-5 dependent adhesion (21) . FN-40 was used at a concentration (100 ug/ml) shown to inhibit binding of VLA-4-positive cells to FN-40-coated plates by 90% (24) . Anti-VCAM-l antibody E1/6 culture supernatant inhibits adhesion oflymphocytes to IL-I -treated endothelial cells (25) , and was also inhibitory in the present study.
The effect of blocking antibodies on adhesion of normal Adhesion of NALM-6 cells to BM-FB was significantly inhibited by CD29 (inhibition 57+12%; n = 3; P < 0.05) and CD49d (inhibition 52±10%; n = 3; P < 0.05), but was not inhibited by anti-fibronectin antibody or soluble FN-40. Adhesion ofReh cells to BM-FB was also blocked by CD49d (inhibition 90±1.3%; n = 3; P < 0.001), but not by anti-fibronectin antibody.
Identification ofVCAM-I on BM-FB. Based on the positive inhibition results with antibodies to VCAM-l and the lack of inhibition with anti-fibronectin antibody or FN-40, evidence for expression ofthe alternative VLA-4 receptor, VCAM-1, on BM-FB was sought. Subconfluent BM-FB were VCAM-I positive by immunofluorescence (Fig. 6) (Fig. 7 a) . In a similar fashion, treatment with phorbol ester enhanced adhesion to BM-FB of mature B cell lines (7-29-6 and WIL-2) to a greater degree (3.7-fold increase) than B precursor cell lines (NALM-6 and Reh; 1 (26) . Our findings are also consistent with the recent description (27) of a 107-kD glycoprotein, possibly a murine VCAM-l equivalent, on thymic stromal cells that mediates adhesion of a thymocyte cell line, and suggest the broad importance of VLA-4 and VCAM-1 in mediating adhesion of mammalian lymphohematopoietic precursor cells.
Subpopulations of normal human bone marrow B cell precursors have been described based on expression of CD10, CD20, CD34, CD45, cytoplasmic Ig, and TdT. We (12) and others (28) have proposed a differentiation sequence of B lineage cells in which the order of CD1O and CD20 expression is: CD10+/CD20-, CDl0+/CD20+, and CD10-/CD20+. We have previously observed that adhesion ofsubpopulations ofnormal B lineage cells to bone marrow derived fibroblasts decreases with increasing maturation (13) .
In order to investigate the applicability of these observations to malignant human B cell precursors, B precursor leukemia cell lines were investigated. The cell lines NALM-6 and Reh demonstrated increased adhesion to BM-FB relative to dermal fibroblasts or fibronectin, and were more adherent to BM-FB than were mature B cell lines. These results are entirely consistent with the adhesion pattern of normal B cells (13) .
Several adhesion proteins were expressed at higher levels in mature B cells than B cell precursors (CD44, LECAM Since these values represent the average of three to six separate experiments, each ofwhich was performed in triplicate, the mean±SEM is shown. Using a paired t test (comparing each blocking study with controls run at the same time), statistically significant inhibition of CDI0/CD20-cell adhesion was observed with CD49d (P < 0.0002), CD29 (P < 0.0005), and VCAM-I (P < 0.002) antibodies. Significant inhibition of CDI0+/CD20' cell adhesion was observed with CD49d (P < 0.005), CD29 (P < 0.002), and VCAM-l (P < 0.05) antibodies. These differences remained highly significant in each case even if unpaired statistical analysis was used. None of the other antibodies resulted in statistically significant blocking of any cell subpopulation.
The binding assays were performed at 37°C since adhesion of B cell precursors to BM-FB was energy dependent. Binding of the most immature subset, CD10+/CD20-, was inhibited by 75% (±4%; n = 4) from 47% to 12%, whereas binding of mature B cells was inhibited by 50% (±3%; n = 4) from 18% to 9% if the adhesion assay was carried out at 4°C in the presence of 0.1% azide. Divalent cation-containing culture medium was used since adhesion of both mature and immature B cells to BM-FB was reduced by > 90% in culture medium with 0. 15% K-EDTA, and by > 95% in Hanks' medium with 0.6% albumin without Ca2" or Mg2". These findings are typical ofintegrin adhesion interactions (17) .
that we observed is equivalent to that previously reported by Kansas and Dailey (16) .
Of the adhesion proteins studied, only VLA4 and VLA-5 were expressed at higher levels in B cell precursors than in mature B cells. These changes in surface marker expression were not simply related to cell size, since B cell subpopulations show similar forward light scatter (12) . In line with the data on normal B lineage cells, VLA-4 and VLA-5 are expressed more intensely by B precursor lines than mature B cell lines, whereas LFA-1, CD44, and CD54 are expressed more intensely by mature B cell lines.
VLA-4 and VLA-5 integrins are of interest since they are both fibronectin receptors, and murine B cells show adhesion to fibronectin which diminishes during development (29) . Mu (33), and macrophages. There is some evidence for a decrease in VLA-4 expression early in the T cell lineage, followed by an increase after activation of mature T cells (34) . Functionally, VLA-4 mediates adhesion of mature germinal center B cells to dendritic cells in lymph node follicles (35) , and is involved in adhesion and function ofT cells and NK cells, as well as human erythroid progenitors (36) .
VLA-4 has two known ligands, fibronectin and VCAM-1, a 100-kD cytokine-induced endothelial adhesion protein that is a member of the immunoglobulin superfamily (37) . VLA-4 is unique since it is the only member of the VLA family that has been reported to mediate cell-cell interactions (38) . VCAM-1 interacts with VLA-4 at a site distinct from the fibronectin binding site (24) .
Neither blocking antibodies to fibronectin nor a soluble fibronectin fragment (FN-40) Antibodies to VCAM-l blocked adherence of B precursor cells to BM-FB to a similar degree as CD49d antibodies, suggesting that VLA-4 is largely interacting with VCAM-1, and not fibronectin or an unidentified ligand. The identification of VCAM-1 as an adhesion receptor on BM-FB for B cell precursors is strengthened by the immunofluorescence and flow cytometry data indicating that BM-FB express VCAM-1. Dermal fibroblasts, which are morphologically similar to BM-FB but do not support adhesion of B cell precursors, are negative for VCAM-1, again suggesting the importance of VCAM-I in supporting adhesion of B cell precursors. The antibody blocking studies do not identify which cells express VLA-4 and which express VCAM-I, since blocking antibody is in contact with both the B cell precursors and BM-FB during the incubation.
However, VCAM-1 is expressed by only BM-FB cells and not B cell precursors, and VLA-4 is expressed by only B cell precursors and not BM-FB, indicating that VLA-4 on the B cell precursor binds to VCAM-l on the marrow-derived fibroblast layer.
VCAM-1 is primarily expressed by activated or inflamed endothelium (39), and not by resting or activated tissue fibroblasts (40) . Therefore, the expression of this molecule by bone marrow-derived adherent cells which have the properties of fibroblasts (7) (42) .
One way in which the affinity of adhesion receptors can be regulated is by protein kinase C activation, as described for LFA-1. In our system, blocking studies do not suggest an important role for LFA-I in adhesion ofresting B cells to BM-FB. After treatment with phorbol esters, however, the adhesion of mature B cells increased, and was partially inhibitable by blocking antibodies to LFA-1. Interestingly, the up-regulated adhesion of phorbol-treated B cell precursors was blocked partially by antibodies to VLA-4 and not LFA-1. There is precedent for up-regulation of VLA-4 affinity by phorbol esters in T cells (41) , although the possibility of phorbol up-regulation of VCAM-1 affinity should be considered, since both the B cell precursors and the BM-FB are exposed to PMA in this system. BM-FB express both VCAM-1 and ICAM-1, and hence can support VLA-4-or LFA-l-mediated adhesion. These results suggest that a single mechanism of B cell activation may result in upregulated adhesion to different substrates, depending on the stage of differentiation of the B cell.
It of B lymphocyte precursors (43) may be due to localized VCAM-1 expression in the marrow. Adhesion of human myeloid progenitors to bone marrow stroma is not inhibited by anti-VLA-4 antibodies (44), suggesting differences in adhesion specificity between lymphoid and myeloid progenitors which may be responsible for different tissue localization ofthese cells within the bone marrow cavity (45) . The functional significance of VLA4/VCAM-l interactions in human B lymphopoiesis is not yet known, although studies in the murine long-term lymphoid culture system (26) suggest that VLA-4 interactions are necessary in B cell development. Fetal human B cell precursors may be capable ofin vitro proliferation in the presence of IL-7 and adherent cells grown from adult human bone marrow (46) . This suggests that the bone marrow-derived adherent cells in our system may be capable ofproviding a genuine microenvironment for B cell lymphopoiesis under the proper culture conditions, permitting investigation of the role of VLA4 and VCAM-l mediated adhesion in lymphopoiesis. 
